An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Stopped In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.

Conditions

• Relapsed or Refractory Acute Myeloid Leukemia (AML)
• Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

Interventions

• DRUG: KRT-232
• DRUG: Cytarabine
• DRUG: Decitabine

Sponsor

Kartos Therapeutics, Inc.